---
name: managing-hypertensive-emergencies
language: en
description: Guides urgent blood pressure management with target reduction rates and IV medication protocols. Use when managing hypertensive crises, selecting IV antihypertensives, or monitoring acute BP reduction.
tags:
  - management
  - cardiology
metadata:
  author: casemark
  practice_areas:
    - Cardiology
    - Interventional Cardiology
    - Electrophysiology
  document_types:
    - Management Report
  skill_modes:
    - Management
    - Coordination
---

# Managing Hypertensive Emergencies

Guides urgent blood pressure management with target reduction rates and IV medication protocols.

## Why This Skill Exists

Hypertensive emergencies — defined as severely elevated BP (often > 180/120 mmHg) with acute end-organ damage — carry mortality rates of 1–2% per hour if untreated. The distinction between hypertensive emergency (end-organ damage present) and hypertensive urgency (elevated BP without acute damage) is critical, as management strategies differ fundamentally: emergencies require IV therapy with controlled rate of BP reduction, while urgencies can be managed with oral agents.

The 2017 ACC/AHA Hypertension Guideline and critical care consensus documents define target reduction rates specific to each end-organ presentation. Overly rapid BP reduction risks watershed infarction, especially in patients with chronic hypertension whose autoregulatory curve is right-shifted.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the current blood pressure (both arms if aortic dissection suspected)? (default: "BP not documented")
2. Is there evidence of acute end-organ damage — which organ system? (default: "End-organ status not assessed")
3. What is the timeline of BP elevation — acute onset or chronically elevated? (default: "Timeline unknown")
4. What is the neurologic examination status? (default: "Neuro exam not documented")
5. What is the current renal function (Cr, BUN, urinalysis with sediment)? (default: "Renal function not provided")
6. Is there chest pain, dyspnea, or signs of aortic dissection? (default: "Cardiac symptoms not assessed")
7. What antihypertensive medications is the patient currently prescribed (compliance)? (default: "Medication adherence not documented")
8. Are there any known secondary causes of hypertension (pheochromocytoma, renal artery stenosis, primary aldosteronism)? (default: "No secondary cause suspected")

### Documents to Request

- Current vital signs with BP in both arms
- Fundoscopic examination findings
- 12-lead ECG
- Chest X-ray
- BMP (Cr, BUN, electrolytes)
- Urinalysis with microscopy (RBC casts, proteinuria)
- Troponin (if chest pain or ECG changes)
- CBC with peripheral smear (if TMA suspected)
- CT head (if neurologic symptoms)
- CT angiogram (if dissection suspected)
- Pregnancy test (if applicable — eclampsia workup)
- Current medication list and compliance assessment

---

## Step 1: Classify Emergency vs. Urgency

**Hypertensive Emergency (requires IV therapy, ICU monitoring):**

| End-Organ Target | Presentation | Key Diagnostics |
|-----------------|-------------|-----------------|
| Brain — hypertensive encephalopathy | Headache, confusion, visual changes, seizures, papilledema | CT/MRI head; fundoscopy |
| Brain — ischemic stroke | Focal neurologic deficits | CT head; CTA |
| Brain — hemorrhagic stroke/SAH | Thunderclap headache, neurologic deficits | CT head |
| Heart — acute HF/pulmonary edema | Dyspnea, rales, S3, JVD | CXR, BNP, echo |
| Heart — ACS | Chest pain, ECG changes, troponin elevation | ECG, troponins |
| Aorta — acute dissection | Tearing chest/back pain, BP differential between arms | CTA aorta |
| Kidney — acute renal injury | Oliguria, rising Cr, hematuria, proteinuria | BMP, UA with microscopy |
| Blood — TMA/MAHA | Schistocytes, thrombocytopenia, elevated LDH | CBC, smear, LDH, haptoglobin |
| Pregnancy — eclampsia/preeclampsia | Seizures, proteinuria, elevated LFTs, thrombocytopenia | Labs, urine protein, fetal monitoring |

**Hypertensive Urgency (no end-organ damage):**
- Severely elevated BP (often > 180/120) but no acute target organ injury
- Manage with oral agents; aim for gradual reduction over 24–48 hours
- Common scenario: medication non-adherence with asymptomatic BP elevation

---

## Step 2: BP Reduction Targets by Presentation

**General Principle:** Reduce MAP by no more than 25% in the first hour, then to 160/100 over the next 2–6 hours, then gradually to normal over 24–48 hours.

**Presentation-Specific Targets:**

| Presentation | First-Hour Target | 2–6 Hour Target | Agent of Choice |
|-------------|-------------------|-----------------|----------------|
| Hypertensive encephalopathy | Reduce MAP by 20–25% | 160/100 | Nicardipine or labetalol |
| Acute ischemic stroke (no tPA) | < 220/120 (permissive) | Maintain < 220/120 | Labetalol or nicardipine |
| Acute ischemic stroke (tPA eligible) | < 185/110 pre-tPA; < 180/105 post-tPA | Maintain target | Labetalol or nicardipine |
| Hemorrhagic stroke | SBP < 140 (INTERACT2/ATACH-2) | Maintain < 140 | Nicardipine or clevidipine |
| Aortic dissection | SBP < 120 AND HR < 60 within 20 min | Maintain target | Esmolol + nicardipine (BB first to prevent reflex tachycardia) |
| Acute pulmonary edema | Reduce MAP by 25% | Afterload reduction | Nitroglycerin or nitroprusside + furosemide |
| ACS | Reduce to relieve ischemia | Titrate to symptoms | Nitroglycerin, esmolol |
| Eclampsia/preeclampsia | SBP < 160, DBP < 110 | Maintain target | IV labetalol or IV hydralazine; magnesium for seizure prophylaxis |
| Pheochromocytoma crisis | Reduce BP gradually | Titrate to symptoms | Phentolamine (alpha-blocker first; never BB alone) |

---

## Step 3: IV Antihypertensive Selection

**First-Line IV Agents:**

| Agent | Mechanism | Dose | Onset | Notes |
|-------|-----------|------|-------|-------|
| Nicardipine | DHP CCB | 5–15 mg/hr IV infusion | 5–15 min | Preferred in most emergencies; titratable |
| Labetalol | Combined α/β-blocker | 20 mg IV bolus, then 0.5–2 mg/min infusion | 5–10 min | Avoid in acute HF, asthma, cocaine |
| Esmolol | β1-selective | 500 mcg/kg bolus → 50–200 mcg/kg/min | 1–2 min | Ultra-short acting; ideal for dissection |
| Clevidipine | DHP CCB | 1–2 mg/hr → titrate by doubling q90s (max 32 mg/hr) | 2–3 min | Ultra-short acting; lipid-based emulsion |
| Nitroglycerin | Venodilator | 5–200 mcg/min | 2–5 min | Best for ACS, pulmonary edema |
| Nitroprusside | Arterial + venous dilator | 0.25–10 mcg/kg/min | Immediate | Cyanide toxicity risk > 48 hours; avoid in renal failure |
| Fenoldopam | D1-agonist | 0.1–1.6 mcg/kg/min | 5–15 min | Renal protective; avoid with glaucoma |
| Hydralazine | Direct vasodilator | 10–20 mg IV q4–6h | 10–20 min | Unpredictable; use in eclampsia when labetalol unavailable |
| Phentolamine | Alpha-blocker | 5–15 mg IV bolus | 1–2 min | Pheochromocytoma/catecholamine excess only |

---

## Step 4: Monitoring and Titration Protocol

**ICU Monitoring Requirements:**
- Arterial line (A-line) for continuous BP monitoring is recommended for all hypertensive emergencies
- If A-line not available: automated cuff cycling every 5 minutes during acute titration, then every 15 minutes once stable
- Continuous telemetry for arrhythmia detection
- Hourly neurologic checks (GCS, pupil response, focal deficits)
- Strict I/O monitoring
- Repeat end-organ labs every 6–12 hours (Cr, troponin, LDH, smear as indicated)

**Titration Rules:**
- Nicardipine: start 5 mg/hr, increase by 2.5 mg/hr every 5–15 minutes to max 15 mg/hr
- Labetalol: 20 mg IV push over 2 min, repeat 40–80 mg every 10 min (max 300 mg total), or start infusion
- Esmolol: adjust infusion by 25–50 mcg/kg/min every 5–10 minutes
- Once BP at target for 6–8 hours on IV: begin oral overlap and wean IV

---

## Step 5: Transition to Oral Therapy

**Oral Agent Selection (overlap with IV for 4–6 hours before discontinuing IV):**

| Agent | Dose | Notes |
|-------|------|-------|
| Amlodipine | 5–10 mg daily | Long-acting CCB; good for nicardipine bridge |
| Lisinopril/Enalapril | 5–20 mg daily | ACEi; avoid in AKI, bilateral RAS, pregnancy |
| Losartan/Valsartan | 25–160 mg daily | ARB alternative to ACEi |
| Labetalol PO | 100–400 mg BID | Bridge from IV labetalol |
| Metoprolol | 25–200 mg daily | Alternative beta-blocker |
| Clonidine | 0.1–0.3 mg BID | Useful for medication non-adherence; risk of rebound |

**Discharge Planning:**
- Confirm stable BP on oral regimen × 24 hours before discharge
- Address root cause of crisis (medication non-adherence, secondary hypertension, substance use)
- Screen for secondary hypertension if indicated (aldosterone/renin, renal duplex, catecholamines, sleep study)
- Close follow-up within 1 week post-discharge

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the classification (emergency vs. urgency) correct with end-organ damage documented?
2. Is the BP reduction target specific to the clinical presentation?
3. Is the IV agent selection appropriate for the organ system involved?
4. Is the monitoring protocol documented (A-line, telemetry, neuro checks)?
5. Is the oral transition plan with follow-up documented?

---

## Quality Audit

- [ ] BP documented in both arms
- [ ] Emergency vs. urgency correctly classified
- [ ] End-organ damage systematically assessed across all systems
- [ ] Presentation-specific BP target documented
- [ ] Rate of BP reduction appropriate (not too fast)
- [ ] IV agent selected based on clinical scenario
- [ ] Drug dose, titration parameters, and max dose documented
- [ ] Continuous monitoring modality specified (A-line preferred)
- [ ] Serial labs ordered to track end-organ recovery
- [ ] Aortic dissection evaluated with BB before vasodilator
- [ ] Oral transition plan with medication, dose, and overlap period
- [ ] Root cause of crisis identified and addressed
- [ ] Follow-up appointment within 1 week documented
- [ ] Medication reconciliation and adherence counseling documented

---

## Guidelines

1. Always distinguish hypertensive emergency from urgency before selecting treatment — urgencies do not need IV therapy and overly aggressive reduction causes harm.
2. In aortic dissection, start beta-blocker BEFORE any vasodilator to prevent reflex tachycardia and increased aortic shear stress — esmolol is preferred.
3. For acute ischemic stroke without thrombolytic candidacy, permissive hypertension (< 220/120) is appropriate — aggressive BP lowering worsens outcomes by reducing perfusion to penumbra.
4. Nitroprusside should be avoided in renal failure and limited to < 48 hours due to cyanide/thiocyanate toxicity risk — use nicardipine or clevidipine instead.
5. Hydralazine is unpredictable in onset and duration — avoid as first-line except in eclampsia when labetalol is unavailable.
6. In pheochromocytoma crisis, NEVER give a beta-blocker before adequate alpha-blockade — unopposed alpha stimulation causes paradoxical BP elevation.
7. Cocaine-associated hypertensive emergency should be treated with benzodiazepines, nicardipine, or phentolamine — avoid beta-blockers (risk of unopposed alpha stimulation).
8. Document the specific reason the BP crisis occurred — medication non-adherence is the most common cause and requires structured counseling, simplified regimens, and close follow-up.